Here we report on the preparation of two hydrogen atom free 3,3'-bi(1,2,4-oxadiazole) derivatives. 5,5'-Bis(fluorodinitromethyl)-3,3'-bi(1,2,4-oxadiazole) was synthesised by fluorination of diammonium 5,5'-bis(dinitromethanide)-3,3'-bi(1,2,4-oxadiazole). For our previously reported analogue 5,5'-bis(trinitromethyl)-3,3'-bi(1,2,4-oxadiazole), a new synthetic route starting from new 3,3'-bi(1,2,4-oxadiazolyl)-5,5'-diacetic acid was developed. In this course also hitherto unknown 5,5'-dimethyl-3,3'-bi(1,2,4-oxadiazole) was isolated. The compounds were characterised by multinuclear NMR spectroscopy, IR and Raman spectroscopy, elemental analysis as well as mass spectrometry. X-ray diffraction studies were performed and the crystal structures for the 5,5'-dimethyl and 5,5'-(fluorodinitromethyl) derivatives are reported. The energetic 5,5'-(fluorodinitromethyl) and 5,5'-(trinitromethyl) compounds do not contain any hydrogen atoms and show remarkable high densities. Furthermore, the thermal stabilities and sensitivities were determined by differential scanning calorimetry (DSC) and standardised impact and friction tests. The heats of formation were calculated by the atomisation method based on CBS-4M enthalpies. With these values and the room-temperature X-ray densities, several detonation and propulsion parameters, such as the detonation velocity and pressure as well as the specific impulse of mixtures with aluminium, were computed using the EXPLO5 code.
The first part of the paper reviews existing technologies for remote marine monitoring with emphasis on latest achievements in the area, including the main common properties and differences between data buoys, moorings, landers, drifters and floats. Novel design for modular smart event triggered marine monitoring platform is proposed in second part of the paper. Mechanical and electrical design of the proposed platform is provided, including early experimental results regarding power consumption. Event trigger mechanism, used for saving battery power consumption, is explained and minimum amount of platform power consumption is determined. Some ideas for future work are also provided.
Many common diseases have a complex genetic basis in which large numbers of genetic variations combine with environmental and lifestyle factors to determine risk. However, quantifying such polygenic effects and their relationship to disease risk has been challenging. In order to address these difficulties we developed a global measure of the information content of an individual's genome relative to a reference population, which may be used to assess differences in global genome structure between cases and appropriate controls. Informally this measure, which we call relative genome information (RGI), quantifies the relative "disorder" of an individual's genome. In order to test its ability to predict disease risk we used RGI to compare single nucleotide polymorphism genotypes from two independent samples of women with early-onset breast cancer with three independent sets of controls. We found that RGI was significantly elevated in both sets of breast cancer cases in comparison with all three sets of controls, with disease risk rising sharply with RGI (odds ratio greater than 12 for the highest percentile RGI). Furthermore, we found that these differences are not due to associations with common variants at a small number of disease-associated loci, but rather are due to the combined associations of thousands of markers distributed throughout the genome. Our results indicate that the information content of an individual's genome may be used to measure the risk of a complex disease, and suggest that early-onset breast cancer has a strongly polygenic basis.
Carbapenems are potent β-lactam antibiotics used to treat serious infections in hospital settings. In comparison to penicillins, cephalosporins or β-lactam/β-lactamase inhibitor they have broad antimicrobial spectrum that includes Gram-positive (e.g. imipenem, doripenem) and Gram-negative bacteria (e.g. meropenem, ertapenem). Imipenem and meropenem have better activity against P. aeruginosa while imipenem and doripenem have better activity than meropenem against Acinetobacter baumannii. Doripenem has the lowest MIC against P. aeruginosa and A. baumannii in comparison to imipenem and meropenem, and it is least susceptible to hydrolysis by carbapenemases. To act on PBPs, carbapenems have to enter the wall of Gram-negative bacteria through outer membrane proteins (porins). Binding to different PBPs they inhibit the synthesis of cell wall finally leading to the death of bacterium [1]. Carbapenem resistance in Gram-negative bacteria can be the consequence of the production of a β-lactamase, expression of efflux pumps, porin loss and alterations in PBPs. Since β-lactams, including carbapenem-like compounds, are natural products of several environmental bacteria and fungi, it is supposed that other bacteria started to produce their intrinsic β-lactamase to give them selective advantage for survival. Thus, several genes encoding different carbapenemases can be found in environmental bacteria like Bacillus anthracis, Serratia fonticola, Pseudomonas cepacia or Acinetobacter spp. as part of their chromosome [1, 2]. Further step in this evolution of resistance was the escape of carbapenemase encoding genes to mobile genetic elements (plasmids, transposons) providing possibility of successful horizontal spread of resistance genes even between different genera [3]. Since this discovery, carbapenemases became global problem. According to the Ambler classification (based on structural similarities) they belong to the class A, B and D [1]. Class A carbapenemases contain serine at their active site and are capable of hydrolyzing all β-lactams, including aztreonam. In this group of carbapenemases, Sme (Sme-1 to Sme-3), IMI (IMI-1-3), NmcA and SFC-1 enzymes are mostly chromosomally encoded, while KPC (KPC- 2 to KPC-13) and GES (GES 1-GES-20) are plasmid encoded. Dominant carbapenemase from this group is KPC, identified in 1996 in North Caroline, USA, now causing many regional outbreaks, with endemicity in northeastern part of the USA, Israel, China, Porto Rico, Colombia, Israel, Greece, and becoming more and more prevalent throughout the Europe [4]. Beside K. pneumoniae, represented by a predominant clone (ST258), it has been found in other Enterobacteriaceae, as well as in P. aeruginosa and A. baumannii–calcoaceticus complex. It is sometimes difficult to be recognized since MICs to carbapenems are in many cases lower than the breakpoints [2, 5]. Class B carbapenemases are also known as metallo-β-lactamase (MBL) since they contain metal ion(s) in their active site. Beside those chromosomally located in environmental bacteria (Bacillus cereus-BCI, BCII, Aeromonas spp-CphA, S. maltophilia-L1), acquired MBL encoding genes are often located in gene cassettes within integron, being part of a plasmid or chromosome. Firstly described acquired MBLs were in Japan in 1991, so called IMP-enzymes (there are now more than 30 derivatives) and are still dominant MBLs in Asian continent causing mainly sporadic outbreaks [6]. VIM-enzymes (there are now more than 30 derivatives) were firstly described in P. aeruginosa but later arisen to Enterobacteriaceae as well, and fastly spread over whole Europe, causing outbreaks in many Mediterranean countries (like Greece, Italy, Turkey). VIM metallo-β-lactamase are now the most prevalent carbapenemase spreading globally, and although largely connected to P. aeruginosa, now reported more often from Enterobacteriacea from Mediterranean countries, particulary Greece and Turkey, with the description of many panresistant strains [6, 7]. Another worrisome metallo-enzyme, arose from India in 2008, namely New-Delhi MBL (NDM-1 ; until now more than ten variants are described), and spread fastly over Indian subcontinet in next few years. NDM-enzymes are mostly associated with nonclonally related isolates of K. pneumoniae and E. coli, but also described in P. aeruginosa and A. baumannii [8]. Beside proven facts that those enzymes exist in isolates spreading in environment, and are carried in general population by enteric flora, the magnitude of the problem potentiates the huge population reservoir from Indian subcontinet and Middle Asia that moves across the world spreading further the resistance genes [9, 10, 11]. Another new source of those enzymes could be the Balkan region [12, 13]. Oxacillinases from molecular class D demonstrating carbapenemase activity are often found in Acinetobacter spp. They are divided into the most globally spread OXA-23 group, found also in environmental isolate of Acinetobacter spp. suggesting the possible natural and not nosocomial source of these genes, OXA-24 group, not so widespread as OXA-23, mostly described in Europe and USA, and OXA-58 group, described in several outbreaks all over the world [14]. The problem became more global with the discovery of OXA-48 in Enterobacteriaceae, particulary in K. pneumoniae and to lesser extent in E. coli, spreading all around the world but specifically in countries close to the Mediterranean Sea [14-16]. Carbapenemase producing Gram-negative bacteria can cause a wide spectrum of infections including bacteraemia, nosocomial pneumonia, wound infections, endocarditis, urinary tract infections. Those infections are often associated with treatment failures, long hospital stay and high mortality rates ; for example attributable mortality for carbapenem resistant P. aeruginosa infections ranged between 51.2 and 95% [17, 18].
Nema pronađenih rezultata, molimo da izmjenite uslove pretrage i pokušate ponovo!
Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo
Saznaj više